Therapeutic Vaccine Reduces Viral Load in Patients With HIV: Presented at AIDS 2010
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Therapeutic Vaccine Reduces Viral Load in Patients With HIV: Presented at AIDS 2010

By Jenny Powers

VIENNA -- July 20, 2010 -- Patients with HIV experienced a slowdown of disease progression resulting from a decreased viral load and increased CD4 cell counts following treatment with a therapeutic vaccine, according to a study presented July 19 at the 18th International AIDS Conference.

Eftyhia Vardas, MD, HIV Vaccines Program, Peri-Natal HIV Research Unit at Chris Hani Baragwanath Hospital, Sowetho, South Africa, reported results of patients who received therapeutic vaccination composed of plasmid DNA.

The primary endpoints of the study were decreased viral loads and increased CD4 counts.

Patients with HIV were randomised to receive the vaccine or placebo at 0, 1, and 3 months, with booster shots at months 19 and 20.

Vaccine therapy resulted in a significant increase in CD4 counts (P = .013) and a 0.5 log decrease in viraemia (P = .002) at 108 weeks of follow-up.

Vaccine effect was emphasised by a decrease in viral load and increase in CD4 after boosting at 64 weeks.

These results were supported by HLA typing which excluded the possibility that the subjects had HLA types that are known to be associated with slower progression.

No vaccine related serious adverse events were observed.

Furthermore, Dr. Vardas remarked that the vaccine is inexpensive to make and is a good treatment option in developing countries.

Funding for this study was provided by FIT Biotech.

[Presentation title: Indicators of Therapeutic Vaccine Effect Using GTU-MultiHIV B Clade DNA in Treatment-Naïve Subtype C HIV-1 Infected Subjects. Abstract MOPDB102]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities